Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees

References

• Miyah Y, Benjelloun M, Lairini S, et al. COVID-19 impact on public health, environment, human psychology, global socioeconomy, and education. Sci World J. 2022 Jan 11;2022:1–8. doi: 10.1155/2022/5578284
   Google Scholar
• WHO Coronavirus (COVID-19) dashboard [internet]. [cited 2022 Jan 16]. Available from: https://covid19.who.int
   Google Scholar
• Zheng J, Deng Y, Zhao Z, et al. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cell Mol Immunol. 2022 Feb;19:(2):150–157.
   PubMed Web of Science ®Google Scholar
• Pasquale S, Gregorio GL, Caterina A, et al. COVID-19 in low- and middle-income countries (LMICs): a narrative review from prevention to vaccination strategy. Vaccines. 2021 Dec;9:(12):1477.
   Web of Science ®Google Scholar
• Stein C, Nassereldine H, Sorensen RJD, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023 Mar 11;401(10379):833–842. doi: 10.1016/S0140-6736(22)02465-5
   PubMed Web of Science ®Google Scholar
• Sjaarda CP, Moslinger E, Tozer K, et al. Distinct age-specific SARS-CoV-2 IgG decay kinetics following natural infection. medRxiv [Internet]. 2021 [cited 2022 Feb 3]; 2021.08.05.21259465. https://www.medrxiv.org/content/10.1101/2021.08.05.21259465v1
   Google Scholar
• Wang X, Guo X, Xin Q, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Dec 17;71(10):2688–2694. doi: 10.1093/cid/ciaa721
   PubMed Web of Science ®Google Scholar
• Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021 Mar 22;12(1):1813. doi: 10.1038/s41467-021-22034-1
   PubMed Web of Science ®Google Scholar
• Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020 Jan 1;9(1):940–948. doi: 10.1080/22221751.2020.1762515
   PubMed Web of Science ®Google Scholar
• Jayathilaka D, Jeewandara C, Gomes L, et al. Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clin Exp Immunol. 2022 Jan 27;208(3):323–331. doi: 10.1093/cei/uxac009
   PubMed Web of Science ®Google Scholar
• Amellal H, Assaid N, Charoute H, et al. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study. PLOS ONE. 2023;18(7):e0288557. doi: 10.1371/journal.pone.0288557
   PubMed Web of Science ®Google Scholar
• Serwanga J, Ankunda V, Sembera J, et al. Rapid, early, and potent spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months. Front Immunol. 2023;14:1152522. doi: 10.3389/fimmu.2023.1152522
   PubMed Web of Science ®Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med. 2020 Sep 10;383(11):1085–1087. doi: 10.1056/NEJMc2025179
   PubMed Web of Science ®Google Scholar
• Yousefi Z, Taheri N, Dargahi M, et al. Long-term persistence of anti-SARS-COV-2 IgG antibodies. Curr Microbiol. 2022;79(4):96. doi: 10.1007/s00284-022-02800-0
   PubMed Web of Science ®Google Scholar
• Cherif I, Kharroubi G, Chaabane S, et al. COVID-19 in Tunisia (North Africa): seroprevalence of SARS-CoV-2 in the General population of the Capital City Tunis. Diagn Basel Switz. 2022 Apr 13;12(4):971. doi: 10.3390/diagnostics12040971
   PubMed Web of Science ®Google Scholar
• Elecsys® Anti-SARS-CoV-2 [Internet]. Diagnostics [cited 2024 Jan 24]. Available from: https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html
   Google Scholar
• Technical Support [Internet]. [cited 2023 Jul 4]. Available from: https://www.genscript.com/product/documents?cat_no=L00847-A&catalogtype=Document-PROTOCOL
   Google Scholar
• COVID-19 detection SARS-CoV-2 neutralization antibody detection kit (RUO) GenScript [Internet]. [cited 2024 Jan 19]. Available from: https://www.genscript.com/covid-19-detection-svnt.html
   Google Scholar
• Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021 Jun;21:(6):395–404.
   PubMed Web of Science ®Google Scholar
• Madanat L, Sager M, O’Connor D, et al. Prognostic value of SARS-CoV-2 anti-RBD IgG antibody quantitation on clinical outcomes in hospitalized COVID-19 patients. Int J Gen Med. 2022 Jun 18;15:5693–5700.
   PubMed Web of Science ®Google Scholar
• Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021 Feb 3;223(2):197–205. doi: 10.1093/infdis/jiaa618
   PubMed Web of Science ®Google Scholar
• Deshpande GR, Kaduskar O, Deshpande K, et al. Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Nov;112:103–110. doi: 10.1016/j.ijid.2021.09.024
   PubMed Web of Science ®Google Scholar
• Plūme J, Galvanovskis A, Šmite S, et al. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients. J Transl Med. 2022 Apr 15;20(1):176. doi: 10.1186/s12967-022-03382-y
   PubMed Web of Science ®Google Scholar
• Lee N, Chan PKS, Ip M, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2006 Feb;35:(2):179–184.
   Web of Science ®Google Scholar
• Feng C, Shi J, Fan Q, et al. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nat Commun. 2021 Aug 17;12(1):4984. doi: 10.1038/s41467-021-25312-0
   PubMed Web of Science ®Google Scholar
• Choe PG, Kang CK, Kim KH, et al. Persistence of neutralizing antibody response up to 1 year after asymptomatic or symptomatic SARS-CoV-2 infection. J Infect Dis. 2021 Sep 17;224(6):1097–1099. doi: 10.1093/infdis/jiab339
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang M, Peng Y, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022 Mar;7:(3):423–433.
   PubMed Web of Science ®Google Scholar
• Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a Systematic Review and pooled analysis. Cureus. 2021;13(10):e19102. doi:10.7759/cureus.19102
   PubMed Web of Science ®Google Scholar
• Epsi NJ, Richard SA, Lindholm DA, et al. Understanding “hybrid immunity”: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) vaccines. Clin Infect Dis. 2023 Feb 1;76(3):e439–49. doi: 10.1093/cid/ciac392
   PubMedGoogle Scholar
• Beaudoin-Bussières G, Laumaea A, Anand SP, et al. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. MBio. 2020 Oct 16;11(5) doi: 10.1128/mBio.02590-20
   PubMed Web of Science ®Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med. 2020 Sep 10;383(11):1085–1087. doi: 10.1056/NEJMc2025179
   PubMed Web of Science ®Google Scholar
• Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021 Feb 19;12(1):1162. doi: 10.1038/s41467-021-21444-5
   PubMed Web of Science ®Google Scholar
• Gerhards C, Thiaucourt M, Kittel M, et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021 Jun;107:221–227. doi: 10.1016/j.ijid.2021.04.080
   PubMed Web of Science ®Google Scholar
• Antinori A, Bausch-Jurken M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis. 2023 Aug 4;228(Suppl 1):S4–12.
   PubMedGoogle Scholar